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Abstract In 2008, a group of Belgian epilepsy experts
published recommendations for antiepileptic drug (AED)
treatment of epilepsies in adults and children. Selection of
compounds was based on the registration and reimburse-
ment status in Belgium, the level of evidence for efﬁcacy,
common daily practice and the personal views and expe-
riences of the authors. In November 2011 the validity of
these recommendations was reviewed by the same group of
Belgian epilepsy experts who contributed to the prepara-
tion of the original paper. The recommendations made in
2008 for initial monotherapy in paediatric patients were
still considered to be valid, except for the ﬁrst choice
treatment for childhood absence epilepsy. This update
therefore focuses on the treatment recommendations for
initial monotherapy and add-on treatment in adult patients.
Several other relevant aspects of treatment with AEDs
are addressed, including considerations for optimal com-
bination of AEDs (rational polytherapy), pharmacoki-
netic properties, pharmacodynamic and pharmacokinetic
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Introduction
The number of antiepileptic drugs (AEDs) currently reg-
istered in Belgium is considerable and still increasing. In
the 1970s only 6 AEDs, benzodiazepines excluded, were
available: phenobarbital, phenytoin, ethosuximide, primi-
done, carbamazepine and valproate. Since the 1990s the
number of approved AEDs has increased exponentially,
though not all of these compounds are marketed (yet).
Although this large choice of AEDs allows tailoring
treatment to the individual patient’s needs, it also makes
selection of the most suitable compound a complicated
task. To provide guidance for the management of epilepsy
in general practice in Belgium, a group of experts pub-
lished recommendations for AED treatment of epilepsies in
adults and children in 2008 [1].
The literature and the views of the authors regarding
initial monotherapy for seizures in paediatric patients
(\16 years) have not changed; the recommendations made
in 2008 are therefore still considered valid [1]. The present
publication focuses on recommendations for AED treat-
ment of epilepsies in adult patients, providing an update
on selection of AEDs for initial monotherapy (for focal
seizures, primary generalized seizures and type of seizures
not yet established) and for add-on treatment of seizures
(focal seizures and primary generalized tonic–clonic
seizures).
The choice of an AED primarily depends on the efﬁcacy
of the compound for controlling the patient’s seizure type
or in a speciﬁc epilepsy syndrome. Other patient-speciﬁc
factors, such as age, presence of concomitant diseases
(including hepatic or renal impairment), use of concomi-
tant medication (including use of other AEDs), sex and
childbearing potential should also be taken into consider-
ation. Factors such as pharmacokinetics, tolerability and
safety of the AED, pharmacokinetic and pharmacodynamic
interaction potential, ease of use and dosing frequency,
availability of pharmaceutical formulations, and possibility
to rapidly obtain seizure control will also play a role in
AED selection.
In addition to providing recommendations for treatment,
the present paper will also address some of these patient-
related and AED-related factors relevant for the selection
of the optimal compound.
Methodology
In 2008, recommendations for the AED treatment of epi-
lepsies in general practice in Belgium were published [1].
These recommendations were prepared by a group of Bel-
gian epilepsy experts, based on guidelines for the treatment
of epilepsies published by the International League against
Epilepsy (ILAE, 2006 [2]), the American Academy of
Neurology (AAN, 2004 [3, 4]), the Scottish Intercollegiate
Guidelines Network (SIGN, 2003 [5]), and the UK National
Institute for Clinical Excellence (NICE, 2004 [6]), and
relevant publications of controlled clinical trials with AEDs
published after the cut-off dates used in these guidelines.
The information from the published guidelines and relevant
clinical studies was evaluated and translated into treatment
recommendations for the Belgian situation, taking into
account the registration status and reimbursement of the
compounds and clinical practice in Belgium.
The discussions resulted in recommendations for initial
monotherapy and add-on treatment in adults and for initial
monotherapy in paediatric patients (\16 years) [1].
In November 2011, the validity of these recommenda-
tions was reviewed by the same group of Belgian epilepsy
experts that contributed to the preparation of the original
paper. Prior to this expert meeting, the scientiﬁc literature
was searched for international treatment guidelines for
epilepsy and relevant controlled clinical trials with AEDs
published after preparation of the recommendations in
2008. The criteria used to determine the relevance of the
clinical trials were the same as in 2008 [1]. No updates on
the ILAE, AAN, SIGN, or NICE guidelines on the treat-
ment of epilepsies have been published since 2008. To the
experts’ knowledge, no new guidelines for epilepsy treat-
ment have been issued by any other scientiﬁc body either.
In a recently published randomized controlled study by
Glauser et al. [7], it was shown that ethosuximide and
valproic acid are more effective than lamotrigine in the
treatment of childhood absence epilepsy, with ethosuxi-
mide being associated with fewer adverse attentional
effects. Based on this study the authors are of the opinion
that both ethosuximide and valproate should be considered
ﬁrst choice in childhood absence epilepsy. This represents
the only change in the 2008 treatment recommendations for
monotherapy in paediatric patients.
Since the publication of the 2008 recommendations,
ruﬁnamide and stiripentol were registered in Belgium;
ruﬁnamide for add-on treatment of patients with Lennox–
Gastaut syndrome and stiripentol as adjunctive therapy in
patients with Dravet’s syndrome. As the 2008 recommen-
dations only covered initial monotherapy in paediatric
patients, these registrations do not imply a change of the
recommendations for children.
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mendations for initial monotherapy and for add-on treat-
ment in adult patients.
The following criteria were used to prepare the treat-
ment recommendations in this update:
• The AED is registered and reimbursed in Belgium.
• The AED with the highest level of evidence for efﬁcacy
is recommended as ﬁrst choice. The deﬁnitions for the
level of evidence were described in detail in the 2008
recommendations [1], and were taken from the ILAE
guidelines for monotherapy [2] and the AAN guidelines
for add-on treatment [4].
• If the level of evidence for different AEDs is the same
or if there is only limited evidence, recommendations
are based on personal views and experiences of the
authors.
The following deﬁnitions are used in the present paper:
First choice First treatment choice
Alternative ﬁrst choice Compound recommended when
certain patient factors (e.g. comorbidity, concomitant
medication) or AED-related factors (e.g. pharmacoki-
netic properties, interaction potential, contraindications,
adverse effect proﬁle) preclude the use of the ﬁrst choice
compound.
Recommendations for treatment
The literature search for papers on monotherapy or add-on
treatment with AEDs published since 2008 did not reveal
any relevant controlled clinical trials that would lead to a
change in the level of evidence for efﬁcacy of the com-
pounds included in Tables 2 and 3.
Initial monotherapy in adults (C16 years)
Recommendations for initial monotherapy of seizures in
adults are presented in Table 2.
Focal seizures with/without secondary generalization
Registered and reimbursed treatment options for mono-
therapy of focal seizures with or without secondary gen-
eralization are carbamazepine, lamotrigine, levetiracetam,
pheneturide, phenobarbital, phenytoin, primidone, topira-
mate, and valproate (Table 1). Since the publication of the
recommendations in 2008, no new treatment options have
become available for this indication.
Carbamazepine and levetiracetam are recommended as
ﬁrst choice. Both compounds have level A evidence for
efﬁcacy [2, 8]. In 2008 levetiracetam was considered
alternative ﬁrst choice (i.e. compound recommended when
certain patient factors or compound-related factors pre-
cluded use of ﬁrst choice carbamazepine) because of the
limited clinical experience with this compound in mono-
therapy. Since 2008 clinical experience with levetiracetam
has increased considerably. Therefore, both levetiracetam
and carbamazepine now are considered ﬁrst choice for
monotherapy of focal seizures with or without secondary
generalization.
Lamotrigine, oxcarbazepine, topiramate and valproate
are alternative ﬁrst choices, with level C or B evidence for
efﬁcacy in the general adult population. For lamotrigine
level A evidence for efﬁcacy was demonstrated in elderly
patients [2].
Primary generalized seizures
The classiﬁcation ‘‘primary generalized seizures’’ includes
tonic–clonic seizures, absences, myoclonic seizures, clonic
seizures, tonic seizures and atonic seizures [11]. The
registered (and reimbursed) indications of AEDs do not
cover all these subtypes of primarily generalized seizures.
Registered and reimbursed AEDs for monotherapy of
primary generalized tonic–clonic seizures are carbamaze-
pine, lamotrigine, phenobarbital, phenytoin, primidone,
topiramate, and valproate. Primidone and valproate are
registered and reimbursed for juvenile myoclonic epilepsy
(Table 1).
The authors consider valproate to be ﬁrst choice for the
treatment of primary generalized seizures, except in
women of childbearing age. Lamotrigine, levetiracetam
and topiramate are alternative ﬁrst choices (Table 2). The
level of evidence for efﬁcacy of the AEDs in the treatment
of primary generalized seizures is not known. Clinical
studies have focused on particular subtypes, such as pri-
mary generalized tonic–clonic seizures or JME. The efﬁ-
cacy of lamotrigine is best documented against primarily
generalized tonic–clonic seizures, absence seizures, and
drop attacks associated with Lennox–Gastaut syndrome
[15]. It is less effective than valproate in syndromes asso-
ciated with myoclonic manifestations or absences [15], and
may induce or aggravate myoclonic seizures. The efﬁcacy
of levetiracetam is best documented against primarily
generalized tonic–clonic seizures, and myoclonic seizures
[15]; information on its efﬁcacy against tonic and atonic
seizures is lacking. The efﬁcacy of topiramate is best
documented against primarily generalized tonic–clonic
seizures and drop attacks associated with Lennox–Gastaut
syndrome. There is no information available on the efﬁcacy
of topiramate against absence seizures.
Carbamazepine may be a valuable alternative ﬁrst
choice for the treatment of primary generalized tonic–
clonic seizures, but is not effective for other types of
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AED Focal seizures with/
without secondary
generalization
Primary generalized seizures Other reimbursed
indications
Approved but not
reimbursed
indications
a Primary generalized
tonic–clonic
seizures
Juvenile myoclonic
epilepsy
Other
Carbamazepine Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy:
adults ? children
Eslicarbazepine
b Eslicarbazepine is
indicated as
adjunctive therapy in
adults with focal
seizures with or
without secondary
generalisation
Ethosuximide Absence
epilepsy;
atonic
seizures,
myoclonia
Felbamate Add-on treatment in
patients with Lennox–
Gastaut syndrome in
adults and children
C4 years (when not
responding to any
other relevant AED)
Gabapentin Add-on treatment:
adults ? children
c
Monotherapy of
partial-onset epilepsy
with/without
secondary
generalization in
adults and children
[12 years
Lacosamide Add-on treatment:
adults ? children
C16 years after
failure of therapy
with at least 3
AEDs
Lamotrigine Monotherapy:
adults ? children
C12 years
Add-on treatment:
adults ? children
d
Monotherapy:
adults ? children
C12 years
Add-on treatment:
adults ? children
a
Add-on treatment of
Lennox–Gastaut
syndrome in adults
and children
e
Levetiracetam Monotherapy:
adults ? children
C16 years
Add-on treatment:
adults ? children
C1 month
Add-on treatment:
adults and
children
C12 years
Add-on treatment of
primary generalized
tonic–clonic seizures
in adults and children
[12 years
Oxcarbazepine Add-on therapy:
adults ? children
C 6 years
Monotherapy of
partial-onset epilepsy
with/without
secondary
generalization in
adults and children
[6 years
Pheneturide Mono- and add-on
therapy:
adults ? children
C2 years
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AED Focal seizures with/
without secondary
generalization
Primary generalized seizures Other reimbursed
indications
Approved but not
reimbursed
indications
a Primary generalized
tonic–clonic
seizures
Juvenile myoclonic
epilepsy
Other
Phenobarbital
f Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy: adults
and children
Phenytoin Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy:
adults ? children
Pregabalin Add-on treatment:
adults
Primidone Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy: adults
and children
Retigabine Add-on treatment:
adults ? children
C18 years after
failure of therapy
with at least 3
AEDs
Ruﬁnamide
g Add-on treatment in
patients with Lennox–
Gastaut syndrome in
adults and children
C4 years (after failure
of at least 2 treatments
with monotherapy or
combinations
including valproate or
topiramate and/or
lamotrigine)
Stiripentol Combination treatment
with valproate and
clobazam of patients
with Dravet’s
syndrome (severe
myoclonic epilepsy of
infancy) when seizures
are insufﬁciently
controlled by
valproate/clobazam
Tiagabine Add-on treatment:
adults ? children
C12 years
Topiramate Monotherapy:
adults ? children
C6 years
Add-on treatment:
adults ? children
C2 years
Monotherapy:
adults ? children
C6 years
Add-on treatment:
adults ? children
C2 years
Add-on treatment in
patients with Lennox–
Gastaut syndrome in
adults and children
C2 years
Valproate Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy:
adults ? children
Mono- and add-on
therapy:
adults ? children
Mono- and
add-on
therapy
for
absence
epilepsy
in adults
and
children
Mono- and add-on
therapy in patients
with Lennox–Gastaut
syndrome, West
syndrome
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123Table 2 Initial monotherapy of seizures in adults (C16 years)
First choice Level of
evidence
for efﬁcacy
Alternative ﬁrst
choice
Level of
evidence
for efﬁcacy
Remarks
Focal seizures with/
without secondary
generalization
Carbamazepine
Levetiracetam
A Valproate B Levetiracetam has a better pharmacokinetic and safety
proﬁle than carbamazepine, with no potential for drug
interactions
For lamotrigine the overall level of evidence for
efﬁcacy is C. Level A evidence for efﬁcacy was
obtained in elderly patients
Lamotrigine
Oxcarbazepine
Topiramate
C
Primary generalized
seizures
Valproate – Lamotrigine
Levetiracetam
Topiramate
– The efﬁcacy of lamotrigine is best documented against
primarily generalized tonic–clonic seizures, absence
seizures, and drop attacks associated with Lennox–
Gastaut syndrome [15] Lamotrigine may induce or
aggravate myoclonic seizures
The efﬁcacy of levetiracetam is best documented
against primarily generalized tonic–clonic seizures,
and myoclonic seizures. Efﬁcacy against tonic and
atonic seizures has not been documented [15]
The efﬁcacy of topiramate is best documented against
primarily generalized tonic–clonic seizures and drop
attacks associated with Lennox–Gastaut syndrome.
Efﬁcacy against absence seizures has not been
documented [15]
First choice ﬁrst treatment choice, Alternative ﬁrst choice compound recommended when certain patient factors (e.g. comorbidity, concomitant
medication) or compound-related factors (e.g. pharmacokinetic properties, interaction potential, adverse effect proﬁle) preclude the use of the
ﬁrst choice compound, Level of evidence for efﬁcacy the criteria used to establish the level of evidence for efﬁcacy are taken from Glauser et al.
[7]
Table 1 continued
AED Focal seizures with/
without secondary
generalization
Primary generalized seizures Other reimbursed
indications
Approved but not
reimbursed
indications
a Primary generalized
tonic–clonic
seizures
Juvenile myoclonic
epilepsy
Other
Vigabatrin Add-on treatment
(last choice):
adults ? children
Monotherapy of
infantile spasms (West
syndrome)
Zonisamide
h Zonisamide is
indicated as
adjunctive therapy in
the treatment of adult
patients with partial
seizures, with or
without secondary
generalization
Source: FAGG/AFMPS 14-12-2011[Federaal Agentschap voor Geneesmiddelen en Gezondheidsproducten/Agence Fe ´de ´rale des Me ´dicaments et des
Produits de Sante ´ (http://www.fagg-afmps.be)]/RIZIV/INAMI 01-01-2012 [Rijksinstituut voor ziekte- en invaliditeitsverzekering (RIZIV); Institut
national d’assurance maladie-invalidite ´ (INAMI); (http://www.inami.fgov.be; http://www.riziv.fgov.be)]
a The mentioned indications are not always registered for all brands/products
b Eslicarbazepine (Exalief; Zebinix) is not (yet) marketed in Belgium
c Some brands specify an age limit of[6 years. Reimbursement criteria do not specify an age limit
d Age limit varies among brands
e For some brands limited to children[2 years
f Magisterial preparation for paediatric use, fully reimbursed
g Ruﬁnamide (Inovelon) is not (yet) marketed in Belgium
h Zonisamide (Zonegran) is not (yet) marketed in Belgium
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myoclonic seizures and absences.
Type of seizures not (yet) established
If starting the AED treatment is required prior to estab-
lishing seizure type, a broad spectrum AED should be used,
such as valproate, lamotrigine, levetiracetam and topira-
mate, taking into account the relative beneﬁts and risks of
each of these compounds.
Add-on treatment of seizures in adult patients
(C16 years)
In the consensus proposal of the ILAE Commission on
Therapeutic Strategies, published in 2010, drug-resistant
epilepsy is deﬁned as ‘‘failure of adequate trials of two
tolerated and appropriately chosen and used AED sched-
ules (whether as monotherapies or in combination) to
achieve sustained seizure freedom’’ [9].
Combination/add-on therapy can be beneﬁcial in
patients who did not respond to monotherapy. Compounds
recommended for add-on treatment are presented in
Table 3. Carbamazepine, gabapentin, lacosamide, lamo-
trigine, levetiracetam, oxcarbazepine, pregabalin, retiga-
bine, tiagabine, topiramate, and valproate are all
considered ﬁrst choice for add-on treatment of focal sei-
zures with or without secondary generalization. For all
newer AEDs the level of evidence for efﬁcacy is A. No
add-on studies have been performed with the older AEDs,
but the efﬁcacy of these compounds is considered to be
established during long-term clinical experience. Lacosa-
mide and retigabine are reimbursed for patients in whom
treatment with at least 3 other AEDs has failed. The other
registered and reimbursed AEDs (pheneturide, phenytoin,
phenobarbital, primidone, and vigabatrin) are not recom-
mended, because of their unfavourable pharmacokinetic
and/or safety proﬁle. Eslicarbazepine
1 and zonisamide
2 are
registered for add-on treatment of focal seizures, but are
not yet marketed/reimbursed in Belgium.
Carbamazepine, lamotrigine, levetiracetam, topiramate
and valproate are recommended as ﬁrst choice for add-on
treatment of primary generalized tonic–clonic seizures. For
lamotrigine, levetiracetam and topiramate the level of
evidence for efﬁcacy is A. Efﬁcacy of carbamazepine and
valproate is considered to be established during long-term
clinical experience. Phenytoin and primidone are not rec-
ommended as ﬁrst choice for this indication, because of
their unfavourable pharmacokinetic and/or safety proﬁle.
The large number of possible combinations of two or
more AEDs has led to an increased interest in combination
strategies. The goals of ‘‘rational polytherapy’’ are to max-
imize seizure control and minimize adverse effects. Ideal
combinations are those which display pharmacodynamic
Table 3 Add-on treatment of seizures in adults (C16 years)
Recommended
AEDs
Remarks
Focal seizures with/without
secondary generalization
Carbamazepine All AEDs are efﬁcacious as add-on treatment of epilepsy in adults
a, and are considered
ﬁrst choice. The AEDs are listed in alphabetical order
Carbamazepine has been used in clinical practice for over 30 years, but has a high
potential for pharmacokinetic interactions
Gabapentin, levetiracetam and pregabalin have the most favourable pharmacokinetic and
safety proﬁle, and no potential for drug interactions
Vigabatrin is also registered and reimbursed for add-on treatment of partial-onset epilepsy,
but should only be used when all other compounds are ineffective, because it has a very
unfavourable safety proﬁle (concentric visual ﬁeld defects)
Lacosamide and retigabine are reimbursed for patients in whom treatment with at least 3
other AEDs has failed
Gabapentin
Lacosamide
Lamotrigine
Levetiracetam
Oxcarbazepine
Pregabalin
Retigabine
Tiagabine
Topiramate
Valproate
Primary generalized
tonic–clonic seizures
Carbamazepine All AEDs are efﬁcacious as add-on treatment of primary generalized tonic–clonic seizures
in adults
a, and are considered ﬁrst choice. The AEDs are listed in alphabetical order Lamotrigine
Levetiracetam
Topiramate
Valproate
a For all newer AEDs the level of evidence for efﬁcacy is A (the criteria used to establish the level of evidence for efﬁcacy are taken from French
et al. [3, 4]. No add-on studies have been performed with the older AEDs; efﬁcacy of these compounds is considered to be established during
long-term clinical experience
1 Exalief; Zebinix.
2 Zonegran.
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123synergism, which ideally may lead to improved efﬁcacy
without a proportional increase in toxicity [12, 13].
TheoreticallyitmaybeassumedthatcombiningAEDswith
different mechanisms of action will provide a better potential
for additive or even synergistic efﬁcacy and/or a more
favourable tolerability proﬁle, and may also be more likely to
be effective against a broad range of seizure types in patients
with refractory epilepsy compared to combining AEDs with
the same mechanism of action [12–14]. There are some indi-
cations from the literature on animal models of seizures and
epilepsy to conﬁrm this view [12–14], but convincing evi-
dence from non-clinical or clinical studies is lacking.
It should be noted that the mechanism-of-action-based
‘‘rational polytherapy’’ approach is seriously hampered by
the lack of knowledge on the processes underlying seizure
generation and propagation, and the lack of knowledge on
the exact mechanism(s) of action of most AEDs, with many
AEDs having multiple pharmacodynamic effects [13].
There is more scientiﬁc evidence in favour of pharma-
codynamic interaction with respect to adverse effects.
When adverse effects of co-administered drugs are similar,
combining these drugs may lead to a ‘‘threshold’’ of tol-
erability being exceeded for that particular side effect. Use
of combinations of drugs that block voltage-dependent
sodium channels (carbamazepine, lacosamide, lamotrigine,
oxcarbazepine) is more likely to produce neurotoxic side
effects, such as dizziness, diplopia and ataxia [12, 14].
Since robust evidence to support rational polytherapy is
still very limited, the choice of drug combinations in
clinical practice will have to be tailored on a case-by-case
basis [13].
Speciﬁc considerations
Pharmacokinetic properties and pharmacokinetic
interaction proﬁle
Most patients with epilepsy are treated for several years
and many need life-long treatment with AEDs. Several
patients may be treated with more than one AED, and the
likelihood of concomitant treatment with drugs for other
diseases (both related and not related to epilepsy) at any
point in their lives is high. The absence of a potential for
drug interactions is therefore an important positive feature
of any AED, which will highly increase its ease of use.
Information on the pharmacokinetic proﬁle of all AEDs
included in Tables 2 and 3 is presented in Table 4. The
pharmacokinetic proﬁle ratings are taken from the hand-
book on epilepsy and epilepsy treatment by Panayiotopo-
ulos [16]. The pharmacokinetic proﬁle rating is based on
the rating system described by Patsalos [17]. The phar-
macokinetic characteristics included in this rating system
are: oral absorption (speed of absorption, bioavailability,
affected or not by food), kinetics (linearity, saturability),
extent of plasma protein binding, extent of renal elimina-
tion, metabolism (hepatic, inducible, autoinducible, active
metabolites), pharmacokinetic drug interactions (affected
by other AEDs, affects other AEDs, affected by other
drugs, affects other drugs), and dosing frequency. All
parameters are scored on a 3-point rating scale, with 3
being the most favourable score. The score presented in
Table 4 is expressed as a percentage of the maximum
possible score. Lacosamide and levetiracetam have the
highest score (96 %), followed by gabapentin and pre-
gabalin (both 89 %). Carbamazepine and valproate have
the lowest scores (50 and 52 %, respectively).
The use of an AED with a high potential for pharma-
cokinetic interactions may alter the plasma concentrations
of the other AEDs in the combination, thereby affecting
their efﬁcacy or increasing the risk of side effects.
Table 4 Pharmacokinetic proﬁle rating and pharmaceutical formu-
lations of the AEDs recommended in Tables 2 and 3
AED Pharmacokinetic
proﬁle rating
of AEDs
a
Pharmaceutical
formulations
Carbamazepine 50 Tablets
Oral solution/syrup
Gabapentin 89 Tablets
Capsules
Lacosamide 96 Tablets
I.V. formulation
b
Lamotrigine 73 Orodispersible tablet
Levetiracetam 96 Tablet
Oral solution
I.V. formulation
Oxcarbazepine 77 Tablets
Pregabalin 89 Capsules
Retigabine NA Tablets
Tiagabine 67 Tablets
Topiramate 79 Tablets
Capsules
Valproate 52 Capsules
Controlled-release capsules
Controlled-release tablets
Enteric-coated capsules
Oral solution/syrup
I.V. formulation
NA no information available
a Data taken from Panayiotopoulos [16]; 3-point rating system based
on the following parameters: oral absorption, kinetics, plasma protein
binding, elimination metabolism, drug interactions and dosing fre-
quency (see Patsalos [17])
b Not reimbursed
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Treatment with AEDs may be associated with adverse
effects. For a complete overview of all adverse effects, the
reader is referred to the summaries of product character-
istics (SmPCs) of the individual AEDs. Handbooks, review
articles and other publications may vary considerably with
respect to their opinions on the most important or clinically
Table 5 Most important adverse effects of the AEDs recommended in Tables 2 and 3
AED Most common adverse effects (occurring in[10 % of the patients)
a Other important adverse events
b
Carbamazepine Central nervous system: dizziness, ataxia, sleepiness
Gastrointestinal: nausea, vomiting
Skin: allergic dermatitis, urticaria (may become serious)
Other: leukopenia, tiredness, increased gamma-GT levels (usually not clinically
relevant)
Diplopia
Weight gain
Hyponatraemia
(aplastic) anaemia
Serious dermatologic reactions
(Stevens–Johnson syndrome)
Gabapentin Central nervous system: dizziness, ataxia, sleepiness
Other: viral infection, tiredness, fever
Weight gain
Lacosamide Central nervous system: dizziness
Gastrointestinal: nausea
Other: headache, diplopia
Dose-related increase in PR-interval
(atrioventricular block)
Lamotrigine Central nervous system: dizziness, ataxia, somnolence
Gastrointestinal: nausea, vomiting
Skin: rash
Other: headache, diplopia, blurred vision
Insomnia
Serious dermatologic reactions
(Stevens–Johnson syndrome)
Hypersensitivity syndrome
Levetiracetam Central nervous system: somnolence
Other: asthenia (tiredness)
Dizziness
Aggressive behaviour (irritability,
hostility)
Oxcarbazepine Central nervous system: dizziness, sleepiness
Gastrointestinal: nausea, vomiting
Other: headache, tiredness, diplopia
Ataxia
Rash
Serious dermatologic reactions
(Stevens–Johnson syndrome)
Hyponatraemia
Pregabalin Central nervous system: dizziness, sleepiness Weight gain
Retigabine Central nervous system: dizziness, somnolence
Other: fatigue
Urinary retention
QT interval prolongation
Confusional state, psychotic symptoms
and hallucinations
Tiagabine Central nervous system: dizziness, somnolence, depressed mood, nervousness,
concentration disturbances, tremor
Other: tiredness
–
Topiramate Central nervous system: dizziness, sleepiness, depression, paraesthesia
Gastrointestinal: diarrhoea, nausea
Other: tiredness, weight loss, nasopharyngitis
Speech disorders
Metabolic acidosis
Kidney stones
Oligohidrosis
Glaucoma
Valproate Central nervous system: tremor
Gastrointestinal: nausea, vomiting, indigestion
Other: weight gain, hair loss
Thrombocytopenia
Hepatotoxicity
Acute pancreatitis
Hyperammonaemia
For a complete overview of adverse events the reader is referred to the SmPCs of the individual products
a Taken from the SmPCs of the individual AEDs. As for valproate no incidence of adverse events is given in the SmPC, the listed adverse effects
are those considered by the experts to be most common
b Taken from 5 recently published reviews [10, 18–21]. The listed ‘‘other important adverse events’’ are those mentioned in at least 3 of these 5
published sources. For lacosamide and retigabine the ‘‘other important adverse events’’ are taken from the SmPC
Acta Neurol Belg (2012) 112:119–131 127
123most relevant adverse effects. Table 5 presents the most
common adverse effects (occurring in more than 10 % of
the patients, as listed in the SmPCs of the AEDs) and
‘‘other important adverse events’’ (mentioned in at least 3
of 5 recently published reviews [10, 18–21]) of the AEDs
listed in Tables 2 and 3.
The adverse effect proﬁle of an AED is a relevant factor
for selecting the optimal compound for an individual
patient. It is for instance not advisable to treat elderly
patients with AEDs with a considerable sedative effect.
Compounds known to induce depression or psychosis
should be avoided in patients with a history of psychiatric
conditions.
The adverse effect proﬁle of AEDs is also relevant when
selecting AEDs for combination therapy (see ‘‘Add-on
treatment of seizures in adult patients’’).
Comorbidity
Epilepsy is often associated with other CNS-related con-
ditions, such as anxiety, depression, migraine, sexual dis-
orders and cognitive problems [22]. In addition, patients
with epilepsy may also suffer from health problems not
related to their epilepsy. The presence of concomitant
diseases should be taken into account when selecting an
AED, since they may form an absolute or relative contra-
indication to the use of certain AEDs (for more information
the reader is referred to the SmPCs of the individual
AEDs).
Elderly
Epilepsy is a common neurologic disorder in the elderly.
The most common causes of new-onset seizures in this age
group are cerebrovascular disease, neurodegenerative dis-
orders and brain tumours, leading to focal seizures with or
without generalization. Carbamazepine, lamotrigine and
gabapentin have level A evidence for efﬁcacy for initial
monotherapy of this type of seizures in the elderly [2, 23].
It should be noted that gabapentin is not reimbursed for
monotherapy. Results of open-label studies indicate that
levetiracetam [24–27] topiramate [28–30] and oxcarbaze-
pine [31–33] are also efﬁcacious and safe in elderly
patients.
Choosing the optimal AED for an elderly patient is
complicated, because of the frequent presence of comorbid
diseases (such as osteoporosis, cognitive deterioration,
parkinsonism, and renal and/or hepatic insufﬁciency) and
use of (chronic) concomitant medication. Altered phar-
macokinetics and a higher susceptibility to the adverse
effects of AEDs, particularly to those related to the nervous
system, should be taken into account. Compounds with a
high potential for drug interactions, for instance due to
induction of metabolic enzymes (such as carbamazepine),
and AEDs having a high probability of adverse effects on
cognition (such as topiramate) should be avoided.
AED treatment in elderly patients should be done with
caution. Dose escalation should be done very carefully, and
maintenance doses will probably be lower than usual in
many cases.
Pregnancy
The risks of AED use during pregnancy are of major
concern. In 2009, the American Academy of Neurology
(AAN) published 3 reports on management issues for
women with epilepsy, based on an evaluation of relevant
articles published between 1985 and 2008 [34–36]. These
reports addressed the following topics: obstetric compli-
cations and change in seizure frequency [34], teratogenesis
and perinatal outcome [35], preconceptional folic acid and
prenatal vitamin K use, the clinical implications of pla-
cental and breast-milk transfer of AEDs, and the effects of
pregnancy on AED plasma levels (including the necessity
of monitoring AED plasma concentrations during preg-
nancy) [36].
Additional information has become available since the
issue of these guidelines (e.g. [37, 38].), but there is still a
considerable lack of knowledge about the effects of AEDs
on the foetus, with the relative risks of the individual
compounds remaining poorly understood. Information
from population-based studies and from data collected by
various pregnancy registries worldwide will have to ﬁll the
knowledge gaps.
Discontinuation of AED treatment prior to or during
pregnancy is usually not an option. It is recommended to
review AED treatment prior to conception, and, if possible,
use monotherapy with the most effective AED at the lowest
effective dose. To avoid high plasma concentrations the use
of slow-release preparations or a multiplication of the
frequency of oral intake may be considered for some
AEDs.
Several publications indicate an increased risk of major
foetal malformations [35, 38–41], and an increased risk of
delayed early cognitive development [35, 41–43] associ-
ated with the use of valproate during pregnancy.
Therefore, use of valproate (particularly at higher dose
levels) and AED polytherapy (particularly combinations
including valproate) during the ﬁrst trimester of pregnancy
should be avoided, to reduce the risk of major congenital
malformations. If possible, valproate and AED polytherapy
should be avoided throughout pregnancy to prevent
reduced cognitive outcomes.
Pregnancy probably causes a decrease in the plasma
concentrations of lamotrigine, phenytoin, and to a lesser
extent of carbamazepine. Plasma concentrations of
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pine (10-monohydroxy derivative) may also be decreased
[36]. Monitoring plasma concentrations of lamotrigine,
carbamazepine, levetiracetam and oxcarbazepine (as its
10-monohydroxy derivative) during pregnancy and after
child birth (for monitoring the risk of overdose) should be
considered. Comparison of plasma concentrations before
and during pregnancy will reveal pregnancy-induced
alterations in pharmacokinetics of the compound(s) in the
individual patient, and may provide a basis for dose
adjustments [41].
Since part of the teratogenicity of AEDs may be related
to an AED-induced decrease in folic acid levels (due to
decreased absorption and increased excretion), supple-
mentation with folic acid (0.4–5 mg/day; in Belgium the
commonly prescribed dose is 4 mg/day) prior to concep-
tion and during the ﬁrst trimester of pregnancy is recom-
mended [36].
Generic substitution
To reduce the cost of health care the use of generics is
strongly advocated by health insurance companies and
governmental institutions. Generic substitution of AEDs is,
however, not without risks.
Approval of generic products is based on bioequivalence
with the original (brand) product. Two products are
considered to be bioequivalent if the 90 % conﬁdence
interval for the ratio of test and reference product for AUC0–t
and Cmax falls within the acceptance interval of 80.00–
125.00 % [44]. Though all generic AEDs are bioequivalent
with the original (brand) product, there may be large dif-
ferences in plasma concentrations between two generic
products, if the bioavailability of the two products is at the
boundaries of the acceptance interval [45]. Moreover, the
design of the studies used to investigate bioequivalence
(mainly single-dose studies in healthy volunteers under
highly standardized conditions), do not guarantee that the
products concerned will also be bioequivalent in an indi-
vidual patient during chronic use [46]. The situation is even
more complicated for compounds with non-linear kinetics
(such as phenytoin), or when there is no clear correlation
between plasma concentration and therapeutic effect.
When considering generic substitution of an AED, the
following should be taken into account. Possible differ-
ences in bioavailability between brands may lead to loss of
seizure control (recurrence of seizures) [47, 48], with major
therapeutic and social consequences for the patient, such as
career restrictions or even loss of employment or loss of
driving license [48, 49]. Differences in bioavailability, and
particularly an increase in peak plasma levels, may lead to
an increase in the frequency and severity of adverse effects
[47, 49].
Differences in appearance of the package or in colour,
shape or taste of the product may confuse the patient,
thereby leading to lower treatment compliance, with the
possibility of break-through seizures [48, 49].
The consequences of generic substitution, such as re-
appearance of seizures and/or an increase in frequency or
severity of adverse effects may lead to additional health
care costs, which may largely surpass the initial savings
earned with the generic substitution [48, 49].
The Belgian Center for Pharmacotherapeutic Informa-
tion (BCFI-CBIP) considers AEDs to be compounds with a
narrow therapeutic margin [50]. In the information pro-
vided on the BCFI-CBIP website all AEDs are categorized
as ‘‘No Switch’’, indicating that switching between brands
and generics is not recommended [51].
Therefore, when a patient is successfully treated with a
particular brand of an AED, it is advised to continue
treatment with that same compound. When choosing
between the brand or one of the generic versions of an
AED the likelihood of continuous supply of the compound
from the same manufacturer should be taken into account
[15, 46]. Prescription of an AED based solely on the active
substance by International Non-proprietary Name (INN),
without any indication of the brand or manufacturer, should
be avoided.
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